[
  {
    "ts": null,
    "headline": "Merck (MRK) Antibody Drug Ifinatamab Deruxtecan Gains Breakthrough Therapy Designation",
    "summary": "Recent advancements in Merck's (MRK) product portfolio, including the FDA's Breakthrough Therapy Designation for ifinatamab deruxtecan and several approvals of their flagship drug KEYTRUDA, are significant highlights. Over the last quarter, Merck's stock price moved up 8%, a positive change in line with the broader market's upward trend of a 16% climb over the year. In parallel, the company's moves, such as share buybacks and potential acquisitions like Verona Pharma, added weight to these...",
    "url": "https://finnhub.io/api/news?id=e6bcfd44f75d85662c8caac458d25a742ba123721c75098cb722c8ee131ff9c8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755624568,
      "headline": "Merck (MRK) Antibody Drug Ifinatamab Deruxtecan Gains Breakthrough Therapy Designation",
      "id": 136432158,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Recent advancements in Merck's (MRK) product portfolio, including the FDA's Breakthrough Therapy Designation for ifinatamab deruxtecan and several approvals of their flagship drug KEYTRUDA, are significant highlights. Over the last quarter, Merck's stock price moved up 8%, a positive change in line with the broader market's upward trend of a 16% climb over the year. In parallel, the company's moves, such as share buybacks and potential acquisitions like Verona Pharma, added weight to these...",
      "url": "https://finnhub.io/api/news?id=e6bcfd44f75d85662c8caac458d25a742ba123721c75098cb722c8ee131ff9c8"
    }
  },
  {
    "ts": null,
    "headline": "MRK's ADC Candidate Gets FDA Breakthrough Therapy Tag for Lung Cancer",
    "summary": "Merck's ifinatamab deruxtecan wins FDA Breakthrough Therapy status for treating adults with extensive-stage small cell lung cancer.",
    "url": "https://finnhub.io/api/news?id=a93944426207fe53890998fe6a58e292b9f48b1e48558193c5d4b7f2a2d411e9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755617820,
      "headline": "MRK's ADC Candidate Gets FDA Breakthrough Therapy Tag for Lung Cancer",
      "id": 136430258,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck's ifinatamab deruxtecan wins FDA Breakthrough Therapy status for treating adults with extensive-stage small cell lung cancer.",
      "url": "https://finnhub.io/api/news?id=a93944426207fe53890998fe6a58e292b9f48b1e48558193c5d4b7f2a2d411e9"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Oncology Drugs Drive Sales in Q2: Will the Trend Continue?",
    "summary": "Pfizer's oncology portfolio, boosted by Seagen and strong drug sales, fuels Q2 growth and positions the company for future cancer treatment gains.",
    "url": "https://finnhub.io/api/news?id=fca0310c9ec21b09e39ec0df49e4f42da96d9936a969295f6cab3a75caca72c2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755608880,
      "headline": "Pfizer Oncology Drugs Drive Sales in Q2: Will the Trend Continue?",
      "id": 136430192,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Pfizer's oncology portfolio, boosted by Seagen and strong drug sales, fuels Q2 growth and positions the company for future cancer treatment gains.",
      "url": "https://finnhub.io/api/news?id=fca0310c9ec21b09e39ec0df49e4f42da96d9936a969295f6cab3a75caca72c2"
    }
  },
  {
    "ts": null,
    "headline": "Can Keytruda Sustain Merck's Growth Through the Rest of 2025?",
    "summary": "MRK banks on Keytruda's soaring sales and new oncology strategies to fuel 2025 growth, even as competition and patent loss loom.",
    "url": "https://finnhub.io/api/news?id=6b096a67d960612b50b9b6ad26359fd811ddbbb0b60b3c285dafa5330af78ea9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755608760,
      "headline": "Can Keytruda Sustain Merck's Growth Through the Rest of 2025?",
      "id": 136430193,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "MRK banks on Keytruda's soaring sales and new oncology strategies to fuel 2025 growth, even as competition and patent loss loom.",
      "url": "https://finnhub.io/api/news?id=6b096a67d960612b50b9b6ad26359fd811ddbbb0b60b3c285dafa5330af78ea9"
    }
  },
  {
    "ts": null,
    "headline": "Vets and Pet-Owners See Gaps in Flea and Tick Prevention, Highlighting Need for Year-Round Care, New Merck Animal Health Global Survey Finds",
    "summary": "RAHWAY, N.J., August 19, 2025--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced results from a new global survey revealing significant gaps in pet owner adherence to flea and tick prevention and concerns among veterinarians, underscoring the need for year-round protection. According to Pet Owner & Vet Perspectives on Parasite Treatment and Prevention: A Global Survey, the majori",
    "url": "https://finnhub.io/api/news?id=8c4b61a547a5a0bc6b53c95b5cb775725b81e1c049f7288664eb5cabe44fd85e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755600300,
      "headline": "Vets and Pet-Owners See Gaps in Flea and Tick Prevention, Highlighting Need for Year-Round Care, New Merck Animal Health Global Survey Finds",
      "id": 136416973,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., August 19, 2025--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced results from a new global survey revealing significant gaps in pet owner adherence to flea and tick prevention and concerns among veterinarians, underscoring the need for year-round protection. According to Pet Owner & Vet Perspectives on Parasite Treatment and Prevention: A Global Survey, the majori",
      "url": "https://finnhub.io/api/news?id=8c4b61a547a5a0bc6b53c95b5cb775725b81e1c049f7288664eb5cabe44fd85e"
    }
  },
  {
    "ts": null,
    "headline": "Merck announces EC approval of Ogsiveo for desmoid tumours",
    "summary": "Ogsiveo's approval is backed by results from the Phase III DeFi trial.",
    "url": "https://finnhub.io/api/news?id=6980dc6573429523174e9b731baa0787bad1c553ed5042b9b1e191a2fd87c5d7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755593620,
      "headline": "Merck announces EC approval of Ogsiveo for desmoid tumours",
      "id": 136416974,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Ogsiveo's approval is backed by results from the Phase III DeFi trial.",
      "url": "https://finnhub.io/api/news?id=6980dc6573429523174e9b731baa0787bad1c553ed5042b9b1e191a2fd87c5d7"
    }
  },
  {
    "ts": null,
    "headline": "A Tweak to Medicare is Good for Merck. Can It Cure the Troubled Stock?",
    "summary": "Shares have plunged by a third in the past year. Investors are worried about expiring patents for Keytruda, the cancer blockbuster.",
    "url": "https://finnhub.io/api/news?id=2f26bb39067d1435157c972397345dae13b36d017d8d3cf708a720e1222d04a0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755579600,
      "headline": "A Tweak to Medicare is Good for Merck. Can It Cure the Troubled Stock?",
      "id": 136416975,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Shares have plunged by a third in the past year. Investors are worried about expiring patents for Keytruda, the cancer blockbuster.",
      "url": "https://finnhub.io/api/news?id=2f26bb39067d1435157c972397345dae13b36d017d8d3cf708a720e1222d04a0"
    }
  },
  {
    "ts": null,
    "headline": "Summit Therapeutics Advances as Trial Outcomes and New Collaboration Drive Optimism",
    "summary": "Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the 11 Best Short Squeeze Stocks to Buy Now. Following mixed results in the clinical trial of Ivonescimab, the company entered a new clinical collaboration with Revolution Medicines. The biopharma company, Summit Therapeutics Inc. (NASDAQ:SMMT) develops oncology therapies. Its lead candidate, Ivonescimab, targeting PD-1 and VEGF, is in […]",
    "url": "https://finnhub.io/api/news?id=7dc24695a5975b35b760ddd9d739ffd775bb83797f419feb652897c68b118d30",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755575022,
      "headline": "Summit Therapeutics Advances as Trial Outcomes and New Collaboration Drive Optimism",
      "id": 136416976,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the 11 Best Short Squeeze Stocks to Buy Now. Following mixed results in the clinical trial of Ivonescimab, the company entered a new clinical collaboration with Revolution Medicines. The biopharma company, Summit Therapeutics Inc. (NASDAQ:SMMT) develops oncology therapies. Its lead candidate, Ivonescimab, targeting PD-1 and VEGF, is in […]",
      "url": "https://finnhub.io/api/news?id=7dc24695a5975b35b760ddd9d739ffd775bb83797f419feb652897c68b118d30"
    }
  }
]